These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36165642)

  • 1. Altered Fc glycosylation of anti-HLA alloantibodies in hemato-oncological patients receiving platelet transfusions.
    van Osch TLJ; Pongracz T; Geerdes DM; Mok JY; van Esch WJE; Voorberg J; Kapur R; Porcelijn L; Kerkhoffs JH; van der Meer PF; van der Schoot CE; de Haas M; Wuhrer M; Vidarsson G
    J Thromb Haemost; 2022 Dec; 20(12):3011-3025. PubMed ID: 36165642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phagocytosis of platelets opsonized with differently glycosylated anti-HLA hIgG1 by monocyte-derived macrophages.
    van Osch TLJ; Steuten J; Nouta J; Koeleman CAM; Bentlage AEH; Heidt S; Mulder A; Voorberg J; van Ham SM; Wuhrer M; Ten Brinke A; Vidarsson G
    Platelets; 2023 Dec; 34(1):2129604. PubMed ID: 36185007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fc galactosylation of anti-platelet human IgG1 alloantibodies enhances complement activation on platelets.
    Van Osch TLJ; Oosterhoff JJ; Bentlage AEH; Nouta J; Koeleman CAM; Geerdes DM; Mok JY; Heidt S; Mulder A; Van Esch WJE; Kapur R; Porcelijn L; Van der Schoot CE; De Haas M; Wuhrer M; Voorberg J; Vidarsson G
    Haematologica; 2022 Oct; 107(10):2432-2444. PubMed ID: 35354253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-HLA antibodies with complementary and synergistic interaction geometries promote classical complement activation on platelets.
    Rijkers M; Schmidt D; Lu N; Kramer CSM; Heidt S; Mulder A; Porcelijn L; Claas FHJ; Leebeek FWG; Jansen AJG; Jongerius I; Zeerleder SS; Vidarsson G; Voorberg J; de Haas M
    Haematologica; 2019 Feb; 104(2):403-416. PubMed ID: 30262558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
    Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S
    Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy.
    Kapur R; Kustiawan I; Vestrheim A; Koeleman CA; Visser R; Einarsdottir HK; Porcelijn L; Jackson D; Kumpel B; Deelder AM; Blank D; Skogen B; Killie MK; Michaelsen TE; de Haas M; Rispens T; van der Schoot CE; Wuhrer M; Vidarsson G
    Blood; 2014 Jan; 123(4):471-80. PubMed ID: 24243971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of pathogen-reduced platelet transfusions on HLA alloimmunization in hemato-oncological patients.
    Saris A; Kerkhoffs JL; Norris PJ; van Ham SM; Ten Brinke A; Brand A; van der Meer PF; Zwaginga JJ
    Transfusion; 2019 Feb; 59(2):470-481. PubMed ID: 30499599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: From mechanisms and determinants to therapeutic prospects.
    Couvidou A; Rojas-Jiménez G; Dupuis A; Maître B
    Front Immunol; 2023; 14():1125367. PubMed ID: 36845153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
    Pereira J; Bronfman L; Bertín P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
    Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of the Platelet Refractory Patient.
    Forest SK; Hod EA
    Hematol Oncol Clin North Am; 2016 Jun; 30(3):665-77. PubMed ID: 27113003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycosylation pattern of anti-platelet IgG is stable during pregnancy and predicts clinical outcome in alloimmune thrombocytopenia.
    Sonneveld ME; Natunen S; Sainio S; Koeleman CA; Holst S; Dekkers G; Koelewijn J; Partanen J; van der Schoot CE; Wuhrer M; Vidarsson G
    Br J Haematol; 2016 Jul; 174(2):310-20. PubMed ID: 27017954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C1q-binding anti-HLA antibodies do not predict platelet transfusion failure in Trial to Reduce Alloimmunization to Platelets study participants.
    Jackman RP; Lee JH; Pei R; Bolgiano D; Lebedeva M; Slichter SJ; Norris PJ
    Transfusion; 2016 Jun; 56(6):1442-50. PubMed ID: 27079754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fc-Glycosylation in Human IgG1 and IgG3 Is Similar for Both Total and Anti-Red-Blood Cell Anti-K Antibodies.
    Sonneveld ME; Koeleman CAM; Plomp HR; Wuhrer M; van der Schoot CE; Vidarsson G
    Front Immunol; 2018; 9():129. PubMed ID: 29445378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of platelet refractoriness in oncohematologic patients.
    Ferreira AA; Zulli R; Soares S; Castro Vd; Moraes-Souza H
    Clinics (Sao Paulo); 2011; 66(1):35-40. PubMed ID: 21437433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Afucosylation of HLA-specific IgG1 as a potential predictor of antibody pathogenicity in kidney transplantation.
    Bharadwaj P; Shrestha S; Pongracz T; Concetta C; Sharma S; Le Moine A; de Haan N; Murakami N; Riella LV; Holovska V; Wuhrer M; Marchant A; Ackerman ME
    Cell Rep Med; 2022 Nov; 3(11):100818. PubMed ID: 36384101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens.
    Saito S; Ota S; Seshimo H; Yamazaki Y; Nomura S; Ito T; Miki J; Ota M; Fukushima H; Maeda H
    Transfusion; 2002 Mar; 42(3):302-8. PubMed ID: 11961234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A specific assay for anti-HLA antibodies: application to platelet donor selection.
    Millard FE; Tani P; McMillan R
    Blood; 1987 Nov; 70(5):1495-9. PubMed ID: 3311206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marginal zone B cells are responsible for the production of alloantibodies following platelet transfusion in mice.
    Couvidou A; Angénieux C; Ruch L; Mangin PH; Gachet C; Maître B
    Blood Adv; 2023 Apr; 7(8):1356-1365. PubMed ID: 36490266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of platelet transfusion refractoriness: the use of platelet transfusions matched for both human leucocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunized patients with leukaemia.
    Kekomäki S; Volin L; Koistinen P; Koivunen E; Koskimies S; Ruutu T; Timonen T; Kekomäki R
    Eur J Haematol; 1998 Feb; 60(2):112-8. PubMed ID: 9508352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
    Amemiya Y
    Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.